MetaCap

Alector (ALEC) vs C4 Therapeutics (CCCC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alector (ALEC) has outperformed C4 Therapeutics (CCCC) over the past year, gaining 88.3% versus a gain of 1.6%. Over five years, ALEC leads with a -88.3% price change compared with -93.2% for CCCC. Alector is the larger company by market cap ($347.6 million vs $325.7 million), about 1.1 times the size, while C4 Therapeutics is growing revenue faster (+1.0% vs -79.1%).

C4 Therapeutics converts more of its revenue into profit, with a net margin of -292.1% versus -679.2%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALEC+88.31%CCCC+1.64%
+127%+45%-37%
Nov 21, 20251 yearNov 20, 2026
ALEC-89.08%CCCC-93.55%
+16%-43%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALEC versus CCCC key metrics
MetricALECCCCC
Share price$2.34$2.48
Market cap$347.63M$325.67M
1-day change+1.52%+1.64%
YTD return+49.68%+29.84%
1-year return+88.31%+1.64%
5-year return-88.28%-93.23%
P/E ratio (TTM)6.31—
EPS (TTM)$0.37$-0.63
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$21.05M$35.95M
Revenue growth (YoY)-79.07%+1.02%
Net income (latest FY)$-142.93M$-104.99M
Operating margin-741.30%-320.53%
Net margin-679.16%-292.08%
52-week high$2.84$5.17
52-week low$1.09$1.69
Distance from 52-week high-17.78%-52.03%
Analyst consensusbuystrong_buy
Avg. price target upside+89.29%+404.03%
Average volume3.34M2.57M
Shares outstanding148.88M131.32M
Employees103104
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ALEC has outperformed CCCC by 86.7 percentage points over the past year.
  • C4 Therapeutics is more profitable, keeping -292.1 cents of every revenue dollar as net income versus -679.2 cents for Alector.
  • C4 Therapeutics grew revenue faster in its latest fiscal year (+1.02% vs -79.07%).

About Alector

ALEC stock →

Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 103 employees

About C4 Therapeutics

CCCC stock →

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 104 employees

ALEC vs CCCC FAQ

Which is bigger, Alector or C4 Therapeutics?

Alector (ALEC) is larger, with a market capitalization of $347.63M compared with $325.67M for C4 Therapeutics (CCCC).

Which stock has performed better over the past year, ALEC or CCCC?

ALEC returned +88.31% over the past 12 months, compared with +1.64% for CCCC (price return, excluding dividends). Past performance does not predict future results.

Are Alector and C4 Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons